Study of enavogliflozin to prevent atrial fibrillation return after heart ablation

This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.

This trial tests whether taking a cholesterol-lowering medicine called ezetimibe alongside the usual care can help prevent atrial fibrillation from coming back after a procedure called catheter ablation. Catheter ablation is a treatment that uses heat or cold to destroy tiny areas of heart tissue that cause irregular heartbeats. For people with persistent atrial fibrillation, this trial may offer a way to improve the long-term success of the ablation.

This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.

This trial tests whether early catheter ablation (a procedure to fix irregular heartbeats) helps people who have both heart failure and atrial fibrillation. It looks at how this treatment affects your heart function and quality of life.

This trial tests whether a catheter procedure that treats atrial fibrillation works better than standard care for people with heart failure with preserved ejection fraction. It aims to improve heart rhythm symptoms and overall outcomes compared with conventional treatment.

This study tests whether a procedure called catheter ablation, which treats irregular heartbeats in atrial fibrillation, can improve outcomes in people who also have heart failure with mildly reduced or preserved pumping function. The procedure aims to restore a normal heart rhythm and may help reduce symptoms.